A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas

被引：0
|
作者：
Wilky, Breelyn A.
Maleddu, Alessandra
Mailhot, Anne
Cartwright, Chelsey
Gao, Dexiang
Tellez, Cristiam Moreno
Powers, Kyle
Kemp, Lindsey
Therrien, Nicholas
Patel, Jaymin M.
Grossman, Joseph Elan
O'Day, Steven
Elias, Anthony D.
机构：
[1] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Univ Colorado, Canc Ctr, Aurora, CO USA
[4] Univ Colorado, Aurora, CO USA
[5] Univ Colorado Anschutz Med Campus, Denver, CO USA
[6] Agenus Inc, Boston, MA USA
[7] Agenus Inc, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11501
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
    Calabro, Luana
    Morra, Aldo
    Fonsatti, Ester
    Cutaia, Ornella
    Amato, Giovanni
    Giannarelli, Diana
    Di Giacomo, Anna Maria
    Danielli, Riccardo
    Altomonte, Maresa
    Mutti, Luciano
    Maio, Michele
    LANCET ONCOLOGY, 2013, 14 (11): : 1104 - 1111
  • [42] First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial
    Sun, Xin
    Zhang, Ranxin
    Xu, Jie
    Xie, Lu
    Guo, Wei
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2022, 15 (06) : 266 - 273
  • [43] First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial
    Xin Sun
    Ranxin Zhang
    Jie Xu
    Lu Xie
    Wei Guo
    Asian Pacific Journal of Tropical Medicine, 2022, 15 (06) : 266 - 273
  • [44] Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
    Furukawa, Junya
    Kakei, Yasumasa
    Murakami, Sae
    Kita, Hiroshi
    Ueki, Hideto
    Hara, Takuto
    Teishima, Jun
    Hinata, Nobuyuki
    Miyake, Hideaki
    Fujisawa, Masato
    Shirakawa, Toshiro
    BMC CANCER, 2025, 25 (01)
  • [45] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [46] Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
    Chen, Xiaofeng
    Wu, Xiaofeng
    Wu, Hao
    Gu, Yanhong
    Shao, Yang
    Shao, Qianwen
    Zhu, Feipeng
    Li, Xiao
    Qian, Xiaofeng
    Hu, Jun
    Zhao, Fengjiao
    Mao, Weidong
    Sun, Jing
    Wang, Jian
    Han, Gaohua
    Li, Changxian
    Xia, Yongxiang
    Seesaha, Poshita Kumari
    Zhu, Dongqin
    Li, Huajun
    Zhang, Junling
    Wang, Guoqiang
    Wang, Xuehao
    Li, Xiangcheng
    Shu, Yongqian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [47] Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial.
    Li, Huan
    Li, Zhaohui
    Yan, Min
    Cui, Xiujie
    Ji, Xuening
    Fang, Fenqi
    Zhang, Yuyang
    Wang, Xiaoxin
    Wang, Yan
    Guo, Xiangyu
    Jing, Mingxi
    Gao, Zhichao
    Cao, Hui
    Dong, Fangyuan
    Wu, Jie
    Jiang, Cui
    Duan, Yangyang
    Li, Xiaorui
    Jiang, Yujun
    Sun, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial
    Yang, Heqi
    Li, Linjuan
    Li, Xiaofen
    Ma, Yuhang
    Yang, Yu
    Cao, Dan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [49] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [50] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Bai, Yuxian
    Xu, Jianming
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345